2,669 U.S. Mesothelioma Cases and 30,633 Globally: Latest SEER, CDC, and WHO/IARC Data (2025–2026)

The CDC U.S. Cancer Statistics dataset confirmed 2,669 new mesothelioma cases in the United States in 2022—the most recent year of complete national incidence data as of early 2026 ^[1]. The IARC/WHO GLOBOCAN 2022 release, published February 2024, counted 30,633 cases worldwide with 25,371 deaths ^[9]. Behind these numbers sits a layered story: U.S. mortality has fallen roughly 33 percent over the past two decades, male incidence is declining while female rates remain stable, and global age-standardized rates are stabilizing rather than collapsing.

How Many New Mesothelioma Cases Are Diagnosed in the U.S. Each Year?

The single most authoritative current U.S. figure is 2,669 new mesothelioma cases in 2022, sourced from the CDC U.S. Cancer Statistics (USCS) dataset ^[5]. The USCS dataset combines incidence data from the CDC's National Program of Cancer Registries with the National Cancer Institute's SEER program to cover 100 percent of the U.S. population—a wider net than SEER alone, which represents approximately 48 percent of Americans ^[7]. The prior year (2021) recorded 2,803 confirmed cases. Over the 20-year stretch from 2003 through 2022, USCS recorded 63,620 total cases.

"When a family asks me how rare this disease is, the honest answer is: rare on a population level, but extraordinarily concentrated in groups with historical asbestos exposure. The 2,669 figure for 2022 looks small until you realize it represents thousands of families navigating a diagnosis that often traces back to a workplace from forty years ago."

The American Cancer Society's annual Cancer Facts & Figures publication projects approximately 3,000 new U.S. mesothelioma cases each year when accounting for registry lag and projection methodology. The National Cancer Database, which captures roughly 72 percent of new U.S. cancer diagnoses through hospital reporting, recorded a mean of 2,417 cases per year between 2004 and 2020. Across all four major U.S. surveillance systems, the consensus annual incidence falls between 2,600 and 3,000 cases.

Data Source Summary

Source	Coverage	Latest Data Year	Annual Cases
CDC U.S. Cancer Statistics (USCS)	100% of U.S. population	2022	2,669
CDC WONDER / NCHS	National mortality data	2022–2023	~2,236 deaths (2022)
SEER Program (NCI)	~48% of U.S. population	2021	2,803 (all registries)
National Cancer Database (NCDB)	~72% of new U.S. cancers	2020	Mean 2,417 / year (2004–2020)
ACS Cancer Facts & Figures	Annual projections	2025 estimate	~3,000

What Is the Current U.S. Age-Adjusted Incidence Rate?

The overall U.S. age-adjusted incidence rate for mesothelioma now stands at 0.6 per 100,000 persons based on the 2022 USCS dataset ^[5]. That figure is a dramatic reduction from 1.08 per 100,000 in 2003—approximately a 40 percent drop in just two decades. SEER data covering 2000 through 2021 show rates in non-Hispanic White individuals declining from 1.3 per 100,000 to 0.8 per 100,000 over that same window ^[7].

The rate divergence by sex is striking. From the USCS dataset:

• Males: overall rate of 1.1 per 100,000, peaking at 16.9 per 100,000 among men aged 85 to 89
• Females: overall rate of 0.3 per 100,000, peaking at 3.4 per 100,000 among women aged 85 to 89

Geographic patterns also matter. Metropolitan incidence dropped from 1.4 per 100,000 in 2004 to 0.8 in 2021, reflecting the historical concentration of shipyards, refineries, and manufacturing plants in metro areas. Non-metropolitan incidence remained stable until 2017 and has only recently begun to decline ^[7].

What Is the Median Age at Mesothelioma Diagnosis?

Mesothelioma remains a disease of older adults. Multiple U.S. databases produce largely consistent figures:

• National Cancer Database (2004–2020): mean age 70, median 73
• SEER-17 (ASCO 2025 study, 2000–2021): median 75 years
• American Cancer Society (current): 70 for pleural; 50s for peritoneal mesothelioma
• CDC general reporting: approximately 72 years

The age distribution skews heavily toward older cohorts: roughly 33.5 percent of patients are diagnosed between ages 71 and 80, and 23.1 percent are over age 80 ^[7]. Fewer than 5 percent of cases occur before age 55. Peritoneal mesothelioma presents at a notably younger median age than the more common pleural form, in part because some non-occupational exposures—including cosmetic talc—can manifest earlier in life.

"Latency is the part most newly diagnosed patients never expect. The fiber inhaled in a 1972 boiler room can sit silent for 40 or 50 years before symptoms appear. That gap is why the median age at diagnosis sits in the 70s and why we are still seeing 2,600-plus cases a year despite decades of regulation."

What Is the Male-to-Female Ratio of Mesothelioma Cases?

Mesothelioma is among the most sex-imbalanced cancers tracked by U.S. registries. The CDC USCS data covering 2003 through 2022 split as 47,973 males (75.4 percent) and 15,647 females (24.6 percent)—a ratio of roughly 3.1 to 1 ^[5]. The National Cancer Database from 2004 to 2020 reports a similar 73.2 to 26.8 split (about 2.7 to 1). CDC mortality data from 1999 through 2020 shows an even sharper skew: roughly 79 percent of mesothelioma deaths occurred among men and 21 percent among women, approximately a 3.8 to 1 ratio ^[11].

The mortality disparity tracks the same direction. The Didier 2025 analysis of CDC mortality data reported an age-adjusted death rate of 14.0 per million for men versus 2.8 per million for women across the 1999 to 2020 period ^[10].

The historical asymmetry tracks the male-dominated workforces in shipbuilding, construction, insulation, power generation, and military service during the mid-20th-century peak of U.S. asbestos use. Among peritoneal mesothelioma cases specifically, the sex distribution approaches parity: women account for 20.5 percent of their mesothelioma diagnoses in the peritoneum versus only 8.1 percent of male cases at that site, a 2.5-fold relative excess.

How Is the U.S. Mesothelioma Incidence Trend Moving?

The U.S. trend is firmly downward, but only in men. SEER and CDC analyses converge on the following:

• Males aged 0 to 74: annual percent change of approximately negative 1.8 percent for all mesothelioma and negative 2.2 percent for pleural mesothelioma in SEER-8 covering 1975 through 2022 ^[7]
• Females aged 0 to 74: rates have been essentially stable, with non-significant drift around zero ^[7]
• Both sexes age 75 and older: incidence is increasing, attributed to population aging and an expanding 75-plus demographic rather than new exposures
• The overall age-adjusted rate fell from 1.08 per 100,000 in 2003 to roughly 0.65 per 100,000 in 2022

The persistent stability of female rates is a meaningful epidemiological signal. While men's incidence has tracked the long retreat from heavy occupational asbestos use after the post-WWII industrial peak, women's rates have not followed the same trajectory. That divergence is consistent with the continued presence of non-occupational exposure pathways—secondary (take-home) asbestos exposure, cosmetic talc, and environmental contamination ^[11].

A 2025 study using SEER-17 data from 2000 through 2021 recorded 8,556 cases inside the SEER catchment and confirmed an average annual percent change in incidence of approximately negative 1.75 percent. SEER-based projections estimate that by 2042, virtually all remaining U.S. cases—roughly 1,600 per year—will represent "background" incidence not attributable to historical occupational asbestos exposure ^[7].

What Do the 2023 U.S. Mortality Numbers Tell Us?

The 2023 mortality figure is the most recent U.S. data point available, released by CDC in 2025: more than 2,100 mesothelioma deaths in 2023 ^[6]. The prior year recorded 2,236 deaths in 2022. A peer-reviewed analysis of CDC mortality data from 1999 through 2020 found 54,905 total mesothelioma-related deaths with an overall age-adjusted mortality rate of 7.5 per million—down from 8.5 per million in 1999 to 5.7 per million in 2020, an annual decline of about 1.9 percent ^[10].

The pattern in female mortality deserves separate attention. The CDC's MMWR analysis of women's mortality from 1999 through 2020 found that absolute deaths among women rose 25 percent (from 489 to 614 annually), even as the age-adjusted female rate declined from 4.83 to 4.15 per million ^[11]. The interpretation: more women are dying because the over-65 female population is growing, not because women are being newly exposed at higher rates.

"The 25 percent rise in absolute deaths among women is one of the clearest signals in the dataset that household and consumer-product asbestos exposure has not gone away. Cosmetic talc, secondary exposure from a husband's work clothes, school buildings, older homes—the pathways are different from a shipyard, but the disease that results is the same."

A peer-reviewed retrospective epidemiological analysis of the 1999 to 2020 CDC WONDER dataset confirmed the male-female mortality gap and the steady annual decline, while flagging persistent demographic disparities across race, ethnicity, and region ^[12].

What Do the IARC and WHO Numbers Show for the Global Picture?

The most current authoritative global figures come from GLOBOCAN 2022 (version 1.1), published by the IARC/WHO Global Cancer Observatory in February 2024 ^[9]:

Metric	GLOBOCAN 2022 (IARC/WHO)
New cases globally	30,633
Global age-standardized incidence rate	0.28 per 100,000
Total deaths globally	25,371
Global age-standardized mortality rate	0.22 per 100,000
Male age-standardized rate	0.46 per 100,000
Female age-standardized rate	0.17 per 100,000

Regional case distribution from GLOBOCAN 2022 shows Europe carrying nearly half of the global burden:

• Europe: 14,734 cases (48.1 percent of global total)
• Asia: 8,597 cases (28.1 percent)
• Northern America: 3,833 cases (12.5 percent)
• Latin America & Caribbean: 1,208 cases (3.9 percent)
• Africa: 1,170 cases (3.8 percent)
• Oceania: 1,091 cases (3.6 percent)

The Global Burden of Disease 2021 analysis, published in 2025, confirmed a modest overall global decline in the age-standardized incidence rate from 1990 to 2021—an estimated annual percent change of negative 0.2 percent—but found that absolute case counts rose substantially from 19,072 in 1990 to 34,511 in 2019, an 81 percent increase driven by population growth and aging. The GBD model projects a stabilization rather than continued decline, with global age-standardized rates in 2039 around 0.33 per 100,000 ^[9]. Countries still using or recently using asbestos—Russia, Kazakhstan, India, China—are expected to see rising incidence through 2030 to 2040 as their long latency cohorts mature.

How Do These Numbers Affect Patients and Families?

For patients newly diagnosed with mesothelioma, the headline statistic is not the 0.6 per 100,000 incidence rate. It is that 2,600 to 3,000 American families per year hear the same diagnosis. Three practical implications follow from the current data:

1. Care should be centralized at high-volume institutions. Mesothelioma is rare enough that most general oncologists see fewer than one new case per year. National Cancer Institute–designated centers with active thoracic-oncology programs and mesothelioma-specific clinical trials handle most of the case volume and most of the immunotherapy and surgical innovation.

2. Latency means the exposure that caused today's diagnosis was usually decades ago. Median age at diagnosis is 73 to 75. Many patients diagnosed in 2026 were occupationally exposed in the 1970s and 1980s; some women diagnosed today were exposed through a spouse's work clothes during that same era, or through asbestos-contaminated cosmetic talc. Both groups remain eligible for compensation under existing trust funds and tort claims.

3. Compensation programs are aligned with the latency reality. More than 60 active asbestos trust funds hold an estimated $30 billion to $35 billion in assets, set aside by manufacturers that filed for bankruptcy after the mid-20th-century litigation wave. State-court tort claims operate in parallel. The legal team at Danziger & De Llano has spent more than 30 years building exposure histories from work records, union files, ship logs, and consumer-product testing—the kind of documentation needed to qualify a claim under either system.

What Does the Trajectory Through 2042 Look Like?

Two long-range projections matter for U.S. patients and policymakers. First, SEER-based modeling suggests that U.S. background incidence will fall to roughly 1,600 cases per year by 2042, with most remaining cases attributed to environmental or non-occupational exposure rather than historical industrial use. Second, the EPA's 2024 risk-management rule under the Toxic Substances Control Act phased out the last category of imported chrysotile asbestos in the United States, removing what had been a residual occupational exposure route in chlor-alkali plants and certain replacement parts ^[13].

Globally, the picture diverges. High–Human Development Index countries with earlier asbestos bans—Germany (annual percent change of negative 4.11 percent), Norway (negative 1.94 percent), Australia (negative 1.54 percent), and the United States (negative 1.75 percent)—continue to register steady declines. Countries that have not banned asbestos are expected to see rising incidence through the next two decades. WHO has projected that global mesothelioma deaths could exceed 38,400 per year in the near term if current exposure patterns in non-ban countries persist ^[9].

How Should Patients Use These Statistics?

The CDC, SEER, and IARC datasets are not just academic. They shape three concrete decisions:

• Diagnostic confidence. A patient presenting with pleural effusion plus an occupational or household asbestos history sits within a recognizable epidemiological pattern. That pattern supports timely biopsy, immunohistochemistry, and referral to a high-volume center rather than watchful waiting.
• Treatment selection. The trial landscape (CheckMate 743, IND.227, BEAT-meso, perioperative nivolumab-ipilimumab) was built from the same cohorts the registries describe. Patients matching those eligibility criteria often have FDA-approved or trial-eligible options.
• Compensation timing. Statutes of limitations vary by state but typically begin running at diagnosis, not at exposure. Counsel familiar with the registries' demographic patterns can quickly identify likely exposure routes—occupation, military service, secondary exposure, cosmetic talc—and match each to the appropriate trust fund or tort defendant.

Families navigating a new mesothelioma diagnosis can review the underlying data through CDC, SEER, and IARC, and they can schedule a free consultation with the team at Danziger & De Llano via dandell.com or by calling (855) 699-5441.

References